Get the Stockscreener App
15.98
1.72%
-0.28
Bausch Lomb Corp stock is traded at $15.98, with a volume of 349.79K.
It is down -1.72% in the last 24 hours and up +7.46% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$16.26
Open:
$16.25
24h Volume:
349.79K
Relative Volume:
0.79
Market Cap:
$5.70B
Revenue:
$5.21B
Net Income/Loss:
$-211.00M
P/E Ratio:
-25.86
EPS:
-0.6179
Net Cash Flow:
$861.30K
1W Performance:
-1.42%
1M Performance:
+7.46%
6M Performance:
-6.50%
1Y Performance:
+14.96%
1-Day Range:
$15.85
$16.41
1-Week Range:
$15.85
$16.92
52-Week Range:
$13.09
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
15.98 | 5.70B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
353.17 | 125.08B | 11.03B | 3.16B | 2.83B | 8.7254 |
BDX
Becton Dickinson Co
|
154.48 | 42.57B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
70.04 | 34.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
38.88 | 32.88B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
198.61 | 28.81B | 5.54B | 1.52B | 1.74B | 10.37 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
BHC5652799 Bond Profile — Key Metrics - TradingView
Bausch + Lomb launches AI-powered digital health platform By Investing.com - Investing.com Nigeria
Bausch + Lomb's Prescription Drug Growth Could Support Q2 Results, RBC Says - Moomoo
Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S. - Yahoo Finance
Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing A Potential 11.54% Upside - DirectorsTalk Interviews
Bausch + Lomb Launches the EyeGility Inserter Preloaded IOL Delivery System - VisionMonday.com
Bausch + Lomb (BLCO) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
(BLCO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA) - The Globe and Mail
Bausch + Lomb launches EyeGility IOL delivery system in U.S. By Investing.com - Investing.com Australia
Bausch + Lomb's BL1107 falls short in phase 2 glaucoma trial, redirects program toward geographic atrophy implant - Ophthalmology Times Europe
Bausch + Lomb Launches EyeGility Inserter Preloaded IOL Delivery System In The United States - marketscreener.com
Bausch + Lomb launches EyeGility IOL delivery system in U.S. - Investing.com
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States - Business Wire
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $21 - Moomoo
(BLCO) Equity Market Report (BLCO:CA) - Stock Traders Daily
Bausch + Lomb's BL1107 fails primary end point in Phase 2 glaucoma trial - Optometry Times
Ophthalmology Devices Market Report Released, Includes - GlobeNewswire
Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others - Yahoo Finance
Bausch + Lomb Corporation (BLCO) Stock Analysis: Examining a Healthcare Leader with 11.68% Potential Upside - DirectorsTalk Interviews
(BLCO) Technical Pivots with Risk Controls (BLCO:CA) - Stock Traders Daily
Bausch + Lomb abandons glaucoma drops after phase 2 failure - MSN
Bausch + Lomb ditches BL1107 in glaucoma after trial miss - The Pharma Letter
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today - Yahoo Finance
Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Benzinga
Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care - marketscreener.com
Price to earnings forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Price to sales forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - BioSpace
Bausch + Lomb (BLCO) Could Be 57% Below Fair Value After Product Updates - Yahoo Finance
Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform - VisionMonday.com
Bausch + Lomb halts glaucoma eye drop program after trial miss - Investing.com UK
Bausch + Lomb halts glaucoma eye drop program after trial miss By Investing.com - Investing.com South Africa
Bausch + Lomb Ends Glaucoma Eye-Drop Development After Missed Trial Endpoint - Moomoo
Bausch to stop glaucoma eye drop development after trial miss - Reuters
BLCO stock stays supported by diversified eye-health portfolio - ad-hoc-news.de
Bausch + Lomb Corporation - Baystreet.ca
Stocks in play: Bausch + Lomb Corporation - The Globe and Mail
Bausch + Lomb introduces Orphia, an AI-powered digital health platform - Chain Drug Review
Bausch + Lomb launches AI-powered digital health platform - Investing.com
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care - marketscreener.com
Bausch + Lomb’s new AI platform aims to free doctors from pre-surgery admin - Stock Titan
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Bausch + Lomb (BLCO) Q3 2025 earnings summary - Quartr
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29 - BioSpace
Bausch + Lomb Corp updates keep long-term strategy in focus - Ad-hoc-news.de
Press Release: Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29 - Moomoo
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):